Optime Care President and CEO, Donovan Quill, was featured in Pharmacy Time on August 24, 2020, with his article, “Therapeutic Opportunities for Patients with Orphan, Ultra-Orphan Disorders During COVID-19 Pandemic and Beyond”.
Patients with orphan and ultra-orphan diseases rely heavily on a support system for adherence to therapy, which has been particularly challenging during the COVID-19 pandemic.
Patients with rare and orphan disorders have grappled with reduced care, isolation, and adherence risks throughout their lives, which leads to an extraordinary impact upon individual outcomes. During the COVID-19 pandemic, these same patients now face heightened stress because many of them are immunosuppressed, conscious of infection, and wary of getting sicker than they already are. As a result, they are hypersensitive to viral threats, more isolated than ever, and struggling to self-protect.
Learn more about how a customized care coordination and telehealth solution based on a patient-first care model provides a proactive, process driven program that educates the patient on potential risks and mitigates the transmission of possible infections, such as COVID-19, in the Pharmacy Times article HERE.
